Xeris Biopharma Holdings Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Public

  • Employees
  • 435

Employees

  • Stock Symbol
  • XERS

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $16.65
  • (As of Friday Closing)

Xeris Biopharma Holdings General Information

Description

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 1375 West Fulton Street
  • Suite 1300
  • Chicago, IL 60607
  • United States
+1 (844)
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Other Devices and Supplies
Industrial Supplies and Parts
Stock Exchange
NAS
Corporate Office
  • 1375 West Fulton Street
  • Suite 1300
  • Chicago, IL 60607
  • United States
+1 (844)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Xeris Biopharma Holdings Stock Performance

As of 13-Nov-2026, Xeris Biopharma Holdings’s stock price is $16.65. Its current market cap is $3.04B with 183M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$16.65 $16.65 $5.25 - $16.88 $3.04B 183M 2.77M -$0.03

Xeris Biopharma Holdings Financials Summary

As of 30-Sep-2026, Xeris Biopharma Holdings has a trailing 12-month revenue of $368M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,910,677 1,468,562 706,949 486,561
Revenue 368,259 291,845 203,070 163,914
EBITDA 28,834 37,589 (19,315) (28,486)
Net Income (6,496) 554 (54,836) (62,255)
Total Assets 423,219 383,527 323,060 322,602
Total Debt 226,066 258,098 271,447 229,191
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Xeris Biopharma Holdings Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Xeris Biopharma Holdings‘s full profile, request access.

Request a free trial

Xeris Biopharma Holdings Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Xeris Biopharma Holdings‘s full profile, request access.

Request a free trial

Xeris Biopharma Holdings Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing t
Pharmaceuticals
Chicago, IL
435 As of 2025

Yardley, PA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Xeris Biopharma Holdings Competitors (37)

One of Xeris Biopharma Holdings’s 37 competitors is Savara, a Formerly VC-backed company based in Yardley, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Savara Formerly VC-backed Yardley, PA
Blueprint Medicines Formerly VC-backed Cambridge, MA
Rhythm Pharmaceuticals Formerly VC-backed Boston, MA
ABIONYX Pharma Formerly VC-backed Balma, France
Crinetics Pharmaceuticals Formerly VC-backed San Diego, CA
You’re viewing 5 of 37 competitors. Get the full list »

Xeris Biopharma Holdings Patents

Xeris Biopharma Holdings Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260248724-A1 Injectable high concentration pharmaceutical formulations and methods of manufacturing and use thereof Pending 25-Feb-2025
WO-2026183248-A1 Injectable high concentration pharmaceutical formulations and methods of manufacturing and use thereof Pending 25-Feb-2025
AU-2023364195-A1 Stable levothyroxine compositions in aprotic polar solvents Pending 19-Oct-2022
EP-4604922-A1 Stable levothyroxine compositions in aprotic polar solvents Pending 19-Oct-2022
US-12514837-B2 Stable levothyroxine compositions in aprotic polar solvents Active 19-Oct-2022 A61K31/198
To view Xeris Biopharma Holdings’s complete patent history, request access »

Xeris Biopharma Holdings Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Xeris Biopharma Holdings Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Xeris Biopharma Holdings‘s full profile, request access.

Request a free trial

Xeris Biopharma Holdings Acquisitions (1)

Xeris Biopharma Holdings’s most recent deal was a Merger/Acquisition with Strongbridge Biopharma for . The deal was made on 05-Oct-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Strongbridge Biopharma 05-Oct-2021 Merger/Acquisition Pharmaceuticals
To view Xeris Biopharma Holdings’s complete acquisitions history, request access »

Xeris Biopharma Holdings ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

35.26 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Xeris Biopharma Holdings’s complete esg history, request access »

Xeris Biopharma Holdings FAQs

  • When was Xeris Biopharma Holdings founded?

    Xeris Biopharma Holdings was founded in 2005.

  • Where is Xeris Biopharma Holdings headquartered?

    Xeris Biopharma Holdings is headquartered in Chicago, IL.

  • What is the size of Xeris Biopharma Holdings?

    Xeris Biopharma Holdings has 435 total employees.

  • What industry is Xeris Biopharma Holdings in?

    Xeris Biopharma Holdings’s primary industry is Pharmaceuticals.

  • Is Xeris Biopharma Holdings a private or public company?

    Xeris Biopharma Holdings is a Public company.

  • What is Xeris Biopharma Holdings’s stock symbol?

    The ticker symbol for Xeris Biopharma Holdings is XERS.

  • What is the current stock price of Xeris Biopharma Holdings?

    As of 13-Nov-2026 the stock price of Xeris Biopharma Holdings is $16.65.

  • What is the current market cap of Xeris Biopharma Holdings?

    The current market capitalization of Xeris Biopharma Holdings is $3.04B.

  • What is Xeris Biopharma Holdings’s current revenue?

    The trailing twelve month revenue for Xeris Biopharma Holdings is $368M.

  • Who are Xeris Biopharma Holdings’s competitors?

    Savara, Blueprint Medicines, Rhythm Pharmaceuticals, ABIONYX Pharma, and Crinetics Pharmaceuticals are some of the 37 competitors of Xeris Biopharma Holdings.

  • What is Xeris Biopharma Holdings’s annual earnings per share (EPS)?

    Xeris Biopharma Holdings’s EPS for 12 months was -$0.03.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process